Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Incidence, Management and Outcome of Post-Transplant Lymphoproliferative Disease after 5797 Solid-Organ Transplants over a 30-Year Period in a Single Hospital

Ana Jimenez Ubieto, Rodrigo Gil Manso, Daniel Gil Alós, María Poza Santaella, Tycho Baumann, Antonia Rodriguez Izquierdo, Marina Quesada Sánchez, Pilar Martinez Sanchez, Carlos Grande, Renata Garcia Gigorro, Maria Calbacho, Santiago Barrio, Joaquin Martinez Lopez

Blood (2023) 142 (Supplement 1): 4490.

https://doi.org/10.1182/blood-2023-189478

Published: 2023

Journal Articles

Personalized Monitoring of Circulating Tumor DNA By a Specific Signature of Trackable Mutations after Chimeric Antigen Receptor t-Cell Therapy in Non-Hodgkin B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 6087.

https://doi.org/10.1182/blood-2023-187057

Published: 2023

Journal Articles

Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years

Adolfo Jesús Sáez Marín, Gema Hernández-Ibarburu, Rafael Alonso Fernández, Jose Maria Sanchez Pina, Paula Lázaro Del Campo, Ana Jimenez Ubieto, Clara Cuellar, Andrea Tamayo Soto, Reyes Mas Babio, Lucia Medina, Maria Calbacho, Rosa Ayala, Joaquin Martinez Lopez

Blood (2023) 142 (Supplement 1): 7064.

https://doi.org/10.1182/blood-2023-180923

Published: 2023

Journal Articles

Key Prognostic Factors in Patients with Relapsed/Refractory Follicular Lymphoma: An Evidence Based Systematic Literature and Medical Review

Ana Jimenez Ubieto, Pau Abrisqueta Costa, Christian Hampp, Shivani Aggarwal, Mohsin Shah, Laura Walsh, Eileen Thorley, Qiufei Ma, Bastian von Tresckow

Blood (2023) 142 (Supplement 1): 7261.

https://doi.org/10.1182/blood-2023-186303

Published: 2023

Journal Articles

Key Prognostic Factors in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Evidence Based Systematic Literature and Medical Review

Bastian von Tresckow, Pau Abrisqueta Costa, Shivani Aggarwal, Christian Hampp, Laura Walsh, Eileen Thorley, Mohsin Shah, Qiufei Ma, Ana Jimenez Ubieto

Blood (2023) 142 (Supplement 1): 7258.

https://doi.org/10.1182/blood-2023-179927

Published: 2023

Journal Articles

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Blood (2023) 142 (Supplement 1): 4899.

https://doi.org/10.1182/blood-2023-181815

Published: 2023

Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Blood (2023) 142 (Supplement 1): 3041.

https://doi.org/10.1182/blood-2023-181650

Published: 2023

Journal Articles

Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study

Blood (2023) 142 (Supplement 1): 786.

https://doi.org/10.1182/blood-2023-186730

Published: 2023

Journal Articles

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 669.

https://doi.org/10.1182/blood-2023-181942

Published: 2023

Journal Articles

Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients

Maria Poza Santaella, Rodrigo Íñiguez, Irene Zamanillo, Tycho S. Baumann, Antonia Rodriguez Izquierdo, Enrique Revilla, Sandra Gomez Rojas, Gloria Perez Segura, Pilar Martinez Sanchez, Carlos Grande, Pilar Sarandeses, Santiago Barrio, Maria Calbacho, Rosa Ayala, Joaquin Martinez-Lopez, Ana Jimenez Ubieto

Blood (2023) 142 (Supplement 1): 4405.

https://doi.org/10.1182/blood-2023-189161

Published: 2023

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Gloria Iacoboni, Angel Serna, Victor Navarro Garces, Ana Jimenez Ubieto, Evelyn Valencia, Alberto Lopez Garcia, Itziar Carro, Sergi Camarillas, Josu Iraola, Lucia Medina, Gala Vega, Maria Pozas, Anna Maria Sureda Balari, Raul Cordoba, Miguel Canales, Francesc Bosch, Pere Barba, Pau Abrisqueta Costa

Blood (2023) 142 (Supplement 1): 310.

https://doi.org/10.1182/blood-2023-184883

Published: 2023

Journal Articles

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Blood (2023) 142 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2023-186101

Published: 2023

Journal Articles

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Blood (2023) 142 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2023-186594

Published: 2023

Journal Articles

Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients

Blood (2023) 142 (Supplement 1): 6168.

https://doi.org/10.1182/blood-2023-186019

Published: 2023

Journal Articles

Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Mariana Bastos-Oreiro, Ana Jimenez-Ubieto, Sonia González de Villambrosia, Raul Cordoba, Elena Pérez Ceballos, EVA Maria DONATO Martin, Ana Muntañola Prat, Hugo Daniel Luzardo Henriquez, Lourdes Escoda, Maria Jesús Peñarrubia, María Pozas, Alberto Lopez-Garcia, Daniel Garcia, Emilia Pardal, Claudia Salazar Lozada, Alejandro Martín García-Sancho

Blood (2022) 140 (Supplement 1): 9501–9503.

https://doi.org/10.1182/blood-2022-166213

Published: 2022

Journal Articles

Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 3514–3515.

https://doi.org/10.1182/blood-2022-166372

Published: 2022

Journal Articles

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

Blood (2022) 140 (Supplement 1): 1849–1851.

https://doi.org/10.1182/blood-2022-166329

Published: 2022

Journal Articles

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Blood (2022) 140 (Supplement 1): 10296–10299.

https://doi.org/10.1182/blood-2022-162638

Published: 2022

Journal Articles

Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

Mariana Bastos-Oreiro, Antonio Gutierrez, Almudena Cabero Martínez, Javier López Jiménez, Paola Sandra Villafuerte Gutierrez, Ana Jimenez-Ubieto, Adolfo De La Fuente, Belén Navarro, Maria Stefania Infante, Raul Cordoba, Jaime Perez De Oteyza, Sonia González de Villambrosia, Raquel Del Campo, Daniel Garcia, Antonio Salar, Juan-Manuel Sancho

Blood (2022) 140 (Supplement 1): 3618–3619.

https://doi.org/10.1182/blood-2022-166027

Published: 2022

Journal Articles

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Blood (2021) 138 (19): 1901–1905.

https://doi.org/10.1182/blood.2021012319

Published: 2021

Includes: Supplemental data

NARROW

Incidence, Management and Outcome of Post-Transplant Lymphoproliferative Disease after 5797 Solid-Organ Transplants over a 30-Year Period in a Single Hospital

Personalized Monitoring of Circulating Tumor DNA By a Specific Signature of Trackable Mutations after Chimeric Antigen Receptor t-Cell Therapy in Non-Hodgkin B Cell Lymphoma

Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years

Key Prognostic Factors in Patients with Relapsed/Refractory Follicular Lymphoma: An Evidence Based Systematic Literature and Medical Review

Key Prognostic Factors in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Evidence Based Systematic Literature and Medical Review

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients

Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only